← 返回

T-bet(+)CD8(+) T 细胞主导微卫星稳定型胃癌的抗 PD-1 反应

英文原题:T-bet(+)CD8(+) T cells govern anti-PD-1 responses in microsatellite-stable gastric cancers.

查看英文原题

T-bet(+)CD8(+) T cells govern anti-PD-1 responses in microsatellite-stable gastric cancers.

PubMed 2025/04/25(内容时间) Nat Commun Q1 · IF 18.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

超过90%的晚期胃癌(GC)为微卫星稳定(MSS)型。与微卫星高度不稳定(MSI-H)胃癌对免疫检查点抑制剂(ICI)的高缓解率相比,未分层的MSS胃癌中仅有10%对ICI产生应答。

在本研究中,我们应用半监督学习对MSS胃癌中潜在的ICI应答者进行分层,实现了高准确度,曲线下面积为0.924。对ICI敏感性胃癌肿瘤微环境的空间分析揭示,其肿瘤区域中存在高水平的T-bet+ CD8+ T细胞浸润。T-bet+ CD8+ T细胞因其增强的肿瘤浸润能力和分泌细胞毒性分子的能力而表现出更优越的抗肿瘤活性。在人源化小鼠模型中,过继转移T-bet+ CD8+ T细胞可增强抗肿瘤免疫,并使免疫忽视型MSS胃癌对ICI敏感。空间RNA测序表明,T-bet+ T细胞与PD-L1+肿瘤细胞之间存在正反馈环路,最终驱动T细胞耗竭,因此可用于ICI治疗。

总之,我们的研究为抗肿瘤免疫的潜在机制提供了见解,并加深了我们对MSS胃癌中ICI应答差异的理解。

展开英文摘要原文

More than 90% of advanced gastric cancers (GC) are microsatellite-stable (MSS). Compared to the high response rate of immune checkpoint inhibitors (ICI) in microsatellite-instability-high (MSI-H) GCs, only 10% of unstratified MSS GCs respond to ICIs. In this study, we apply semi-supervised learning to stratify potential ICI responders in MSS GCs, achieving high accuracy, quantified by an area under the curve of 0. 924. Spatial analysis of the tumor microenvironment of ICI-sensitive GCs reveals a high level of T-bet+ CD8 + T cell infiltration in their tumor compartments.

T-bet+ CD8 + T cells exhibit superior anti-tumor activity due to their increased ability to infiltrate tumors and secrete cytotoxic molecules. Adoptive transfer of T-bet+ CD8 + T cells boosts anti-tumor immunity and confers susceptibility to ICIs in immune-ignorant MSS GCs in a humanized mouse model.

Spatial RNA sequencing suggests a positive-feedback loop between T-bet+ T cells and PD-L1+ tumor cells, which eventually drives T cell exhaustion and can therefore be leveraged for ICI therapy. In summary, our research provides insights into the underlying mechanism of anti-tumor immunity and deepens our understanding of varied ICI responses in MSS GCs.

论文信息

作者
Tang S、Che X、Wang J、Li C、He X、Hou K、Zhang X、Guo J
第一作者单位
Department of Medical Oncology, The First Hospital of China Medical University, No. 155, Nanjing Street, Shenyang, Liaoning, China.China
通讯作者单位
Department of Medical Oncology, The First Hospital of China Medical University, No. 155, Nanjing Street, Shenyang, Liaoning, China. ypliu@cmu.edu.cn.China
期刊
Nature communications2025 Apr 25
原文标识
PubMed 40280928 · DOI 10.1038/s41467-025-58958-1